Non-small cell lung cancer (NSCLC) is still the leading cause of cancer-related death, and
the treatment of advanced NSCLC relies on systemic treatments. During the last decade …

Introduction In retrospective analyses of patients with nonsquamous non–small-cell lung
cancer treated with pemetrexed, low thymidylate synthase (TS) expression is associated …

Tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR) are becoming the
standard treatment option for patients with advanced non-small cell lung cancer (NSCLC) …

Background Tumor molecular profiling from patients experiencing exceptional responses to
systemic therapy may provide insights into cancer biology and improve treatment tailoring …

Individuals with cancer are at increased risk of developing new‐onset diabetes mellitus and
hyperglycaemia, and an estimated 20% of people with cancer already have an underlying …

Summary Background In Japan, docetaxel, a cytotoxic monotherapy, is the standard drug
administered to older patients with advanced non-small-cell lung cancer (NSCLC) …

Background: Although immune checkpoint inhibitors (ICIs) have improved survival for
advanced wild-type non-small cell lung cancer (NSCLC), a lack of direct comparisons of …

In the last decade, major progress in the treatment of advanced non-small-cell lung cancer
has been made through the better understanding of the molecular biology of lung cancer …

Background Canada has an established publicly funded health care system with a complex
drug approval and funding process. After proof of efficacy (POE; key publication/presentation …

Objective The purpose of the study was to assess the efficacy and safety of using Chinese
herbal medicine (CHM) as maintenance therapy considering the survival of advanced non …